Indian drug majors focus on portfolio selection, as US generics outlook remains competitive

As the US market prepares to go through a major upcycle following a seven-year downcycle, with numerous key indicators aligning at the same time, Indian pharmaceutical companies are waiting in the wings, poised to leverage the significant opportunity in the small molecule patented drugs segment, reports The Pharma Letter’s India correspondent.

Around 254 small molecule drugs are coming off patent this year, opening up significant opportunities for generic manufacturers, with certain therapeutic areas, including oncology, central nervous system, diabetes, cardiovascular and anti-infectives, offering greater potential opportunities.

An increase in exports to the regulated markets in the USA and Europe is also expected.